# 2025-11822: FDA Retires Another COVID Test From Its Emergency-Use Era

2025-11822, Revocation of Authorization of Emergency Use of In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-05-28; PRIA reads it as touching household money (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11822
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11822
- Title: Revocation of Authorization of Emergency Use of In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27321
- Published: 2025-06-26
- Effective: 2025-05-28
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Retires Another COVID Test From Its Emergency-Use Era

## Summary

The FDA has officially ended the emergency use approval for Cepheid’s Xpert Xpress COVID-19 test as of May 28, 2025, because the company asked for it. This means the test can no longer be used under emergency rules, but it doesn’t affect other COVID-19 tests. Labs and healthcare providers should plan accordingly, but there’s no direct cost impact for the public.

## Abstract

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Cepheid for the Xpert Xpress SARS-CoV-2 test. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocation, which includes an explanation of the reason for revocation, is reprinted at the end of this document.

## Effects PRIA read

- Cepheid Xpert Xpress EUA Revoked: mixed, low. The FDA revoked the Emergency Use Authorization (EUA) for Cepheid’s Xpert Xpress SARS-CoV-2 test effective May 28, 2025, so that specific test can no longer be used under EUA. Cepheid told FDA that all its U.S. customers transitioned to the Xpert Xpress SARS-CoV-2 plus product (authorized under EUA…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11822 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11822/revocation-of-authorization-of-emergency-use-of-in-vitro-diagnostic-device-for-detection-andor)
- [2025-11822 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11822.pdf)

## Related
- [Previous: 2025-11820, Public Water System Supervision Program Revision for New York; Notice of Approv…](https://policyrisk.com/federal-register/2025-11820)
- [Next: 2025-11823, Meeting of the Interagency Task Force on Veterans Small Business Development](https://policyrisk.com/federal-register/2025-11823)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11822 (as of 2026-11-05).
